% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • kevinmik kevinmik Apr 24, 2013 6:59 PM Flag

    Afrezza's Market Potential Is Greatly Under Appreciated.....

    Afrezza will be the first ever insulin product to treat early stage Type II diabetes all the way through late stage Type II and Type I. The market opportunity will begin with Type II patients who are failing Metformin therapy to become the new next gold standard treatment choice after Metformin, over all other diabetes medications including Oral and GLP-1 drugs. The combined sales of all non-insulin diabetes drugs sold is now well over $10 billion annually and Afrezza has a very good chance to take away a lot of those sales post approval. Then you have Afrezza opportunity for Type I, which could see it become the #1 rapid acting insulin sold globally. The American Diabetes Association is advocating introducing insulin use into earlier stage of Type II and Afrezza is the only insulin product that has the potential to serve that market. While all other diabetes medications approved over the past 50 years have enjoyed commercial success the truth is they are are only stimulants that help the body's craving for more insulin and for the most part the fix is usually temporary (a few years) and came with safety concerns. While insulin has been around for over 80 years, safety and delivery issues has kept it from seeing wide spread use and has restricted its use to only benefit diabetics who are at the late stage of the disease when their body's were no longer producing enough insulin. Well after 80 years, we are now on the cusp of seeing insulin treatment finally extend its benefit to include the entire diabetes population from early stage Type II, all the way through late stage Type II and all of Type I. The market is bigger than anyone is estimating and is definitely not being factored into Afrezza's potential sales or Mannkind's potential stock price. JMO

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.920.00(+0.01%)Aug 23 4:00 PMEDT